Patents by Inventor David J. Glass

David J. Glass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200031940
    Abstract: The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.
    Type: Application
    Filed: March 20, 2018
    Publication date: January 30, 2020
    Inventors: Anthony ROSENZWEIG, Jason D. ROH, David J. GLASS
  • Patent number: 8445434
    Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: May 21, 2013
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David J. Glass, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
  • Publication number: 20120195896
    Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.
    Type: Application
    Filed: March 9, 2012
    Publication date: August 2, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: David J. GLASS, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
  • Patent number: 8158581
    Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: April 17, 2012
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David J. Glass, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
  • Publication number: 20110020342
    Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.
    Type: Application
    Filed: September 30, 2010
    Publication date: January 27, 2011
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: DAVID J. GLASS, GEORGE D. YANCOPOULOS, THOMAS J. DALY, NICHOLAS J. PAPADOPOULOS
  • Patent number: 7837999
    Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: November 23, 2010
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David J. Glass, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
  • Patent number: 7781404
    Abstract: Pharmaceutical compositions containing a chimeric protein comprising an IGF1 and an IGF2 component and optionally (F), a fusion component, and/or a signal sequence, are provided. The chimeric protein exhibits improved activity relative to the native IGF1 or IGF2 polypeptide. Further, therapeutic methods for treating IGF1 insufficiency diseases or conditions using the pharmaceutical compositions of the invention are also provided. The diseases or conditions treatable with the methods include muscle atrophy as a result of, for example, aging, cachexia, rheumatoid arthritis, diabetes, disuse or immobilization of muscle, and the like, as well as dwarfism and myocardial infarction.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: August 24, 2010
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: David J. Glass
  • Patent number: 7632503
    Abstract: A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a preferred embodiment, the targeting fusion polypeptide targets muscle and is useful to treat a muscle-related disease or condition, such as muscle atrophy.
    Type: Grant
    Filed: February 14, 2008
    Date of Patent: December 15, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres, David J. Glass
  • Publication number: 20090175864
    Abstract: Pharmaceutical compositions containing a chimeric protein comprising an IGF1 and an IGF2 component and optionally (F), a fusion component, and/or a signal sequence, are provided. The chimeric protein exhibits improved activity relative to the native IGF1 or IGF2 polypeptide. Further, therapeutic methods for treating IGF1 insufficiency diseases or conditions using the pharmaceutical compositions of the invention are also provided. The diseases or conditions treatable with the methods include muscle atrophy as a result of, for example, aging, cachexia, rheumatoid arthritis, diabetes, disuse or immobilization of muscle, and the like, as well as dwarfism and myocardial infarction.
    Type: Application
    Filed: February 26, 2009
    Publication date: July 9, 2009
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventor: David J. Glass
  • Patent number: 7521211
    Abstract: A chimeric protein comprising an IGF1 and an IGF2 component and optionally a fusion component (F) and/or a signal sequence, exhibiting improved activity relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: April 21, 2009
    Assignee: Regeneron Pharmaceuticals, Inc
    Inventor: David J. Glass
  • Publication number: 20090069235
    Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.
    Type: Application
    Filed: June 6, 2008
    Publication date: March 12, 2009
    Inventors: David J. GLASS, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
  • Publication number: 20080199479
    Abstract: A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a preferred embodiment, the targeting fusion polypeptide targets muscle and is useful to treat a muscle-related disease or condition, such as muscle atrophy.
    Type: Application
    Filed: February 14, 2008
    Publication date: August 21, 2008
    Inventors: Trevor Stitt, Esther Latres, David J. Glass
  • Patent number: 7396918
    Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.
    Type: Grant
    Filed: January 6, 2006
    Date of Patent: July 8, 2008
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David J. Glass, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
  • Patent number: 7355018
    Abstract: A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a multimerizing component and/or (iv) a signal sequence. In a preferred embodiment, the targeting fusion polypeptide targets muscle and is useful to treat a muscle-related disease or condition, such as muscle atrophy.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: April 8, 2008
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: David J. Glass
  • Patent number: 7122648
    Abstract: The present invention provides for nucleic acid sequences that encode novel mammalian intracellular signaling polypeptides, designated MINC102. The invention also provides assay systems that may be used to detect and/or measure agents that bind the MINC102 gene product. The present invention also provides for diagnostic and therapeutic methods for treating muscle atrophy by inhibiting expression or activity of MINC102.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: October 17, 2006
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: David J. Glass
  • Patent number: 6852838
    Abstract: The present invention provides for a gene, designated as musk, that encodes a novel tyrosine kinase receptor expressed in high levels in denervated muscle. The invention also provides for an isolated polypeptide which activates MuSK receptor. The invention further provides for a polypeptide which is functionally equivalent to the MuSK activating polypeptide. The invention also provides assay systems that may be used to detect and/or measure ligands that bind the musk gene product. The present invention also provides for diagnostic and therapeutic methods based on molecules that activate MuSK.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: February 8, 2005
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David M. Valenzuela, David J. Glass, David C. Bowen, George D. Yancopoulos
  • Publication number: 20040214285
    Abstract: A HIV-specific fusion polypeptide, comprising (a) one or more domains which comprise a cellular co-receptor protein, or a fragment, derivative, or functional equivalent thereof; (b) one or more domains which comprise a cellular receptor protein, or a fragment, derivative, or functional equivalent thereof; and optionally (c) a multimerizing component, and (d) one or more domains of a viral protein, or a fragment or derivative thereof. In specific embodiments, the HIV-specific fusion protein is a multimer capable of binding an HIV particle, and is useful for the treatment of HIV infections.
    Type: Application
    Filed: January 30, 2004
    Publication date: October 28, 2004
    Inventors: David J. Glass, Margaret Karow, Eric Smith
  • Publication number: 20040018547
    Abstract: The present invention provides for nucleic acid sequences that encode novel mammalian intracellular signaling polypeptides, designated MINC102. The invention also provides assay systems that may be used to detect and/or measure agents that bind the MINC102 gene product. The present invention also provides for diagnostic and therapeutic methods for treating muscle atrophy by inhibiting expression or activity of MINC102.
    Type: Application
    Filed: July 18, 2003
    Publication date: January 29, 2004
    Inventor: David J. Glass
  • Publication number: 20030219739
    Abstract: The present invention provides for nucleic acid sequences that encode novel mammalian intracellular signaling polypeptides, designated MURF1, MURF3, or MA-61. The invention also provides assay systems that may be used to detect and/or measure agents that bind the MURF1 or MAFBXgene product. The present invention also provides for diagnostic and therapeutic methods based on the interaction between MURF1 or MAFBXand agents that initiate signal transduction or inhibition of ubiqutination through binding to MURF1 or MA-61, inhibiting the mRNA expression of MURF1, MURF3, or MA-61, or inhibiting the MURF, MURF3, or MAFBXpathway.
    Type: Application
    Filed: January 30, 2002
    Publication date: November 27, 2003
    Inventors: David J. Glass, Sue C. Bodine
  • Publication number: 20030129686
    Abstract: The present invention provides for nucleic acid sequences that encode novel mammalian intracellular signaling polypeptides, designated MURF1, MURF3, or MA-61. The invention also provides assay systems that may be used to detect and/or measure agents that bind the MURF1 or MAFBXgene product.
    Type: Application
    Filed: January 30, 2002
    Publication date: July 10, 2003
    Inventors: David J. Glass, Sue C. Bodine